ABBVIE INC. (ABBV)
Clinical trial NCT05210803 updates: 1. phase: not set → PHASE2 2. completion date: 2028-03-01 → 2031-07-01 3. primary completion date: 2028-03-01 → 2031-07-01 4. enrollment: 115 → 116 participants 5. study type: OBSERVATIONAL → INTERVENTIONAL 6. allocation: not set → NON_RANDOMIZED 7. intervention model: not set → PARALLEL 8. primary purpose: not set → TREATMENT 9. masking: not set → NONE 10. collaborators added: REGENXBIO Inc.
📉 **NEGATIVE** • Medium confidence analysis (69%) • Mild negative clinical indicator • Limited downside risk **Sentiment:** Negative (20%) **Content type:** Clinical